Posted by Michael Wonder on 08 Jul 2022
NICE recommends Opdivo as post-surgery treatment
8 July 2021 - The therapy will be used for specific muscle invasive urothelial cancer patients
Bristol Myers Squibb has announced that NICE has issued a final appraisal determination recommending Opdivo (nivolumab) for the adjuvant treatment of adult patients with muscle invasive urothelial carcinoma.
